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Abstract Pituitary progenitor or stem cells present in the pituitary primordium
during development are the source of hormone-producing cells of the adult pitui-
tary. These stem cells are maintained in the adult tissue and they can be recruited to
maintain or replenish differentiated pituitary cells. We currently have only limited
insight into the mechanisms that trigger progenitor engagement into one or the
other pituitary differentiation pathway. While transcription factors that drive ter-
minal differentiation have been identified for different lineages, current evidence
suggests that initial engagement of progenitors into differentiation may be due to
earlier-acting factors. One such factor expressed at the transition between progen-
itor and differentiated state was identified in the intermediate lobe; this factor, Pax7,
exerts its action through a pioneer factor activity. Pioneer transcription factors have
the unique ability to bind target sequences in compacted chromatin and to initiate
chromatin “opening” for recruitment of other transcription factors. Pax7 accom-
plishes this process on about 2500 enhancers genome-wide, allowing for Tpit
recruitment at a subset for implementation of the melanotrope-specific program
of gene expression. Current knowledge about this process is reviewed here, together
with a discussion of future challenges in order to understand the unique properties
of pioneer transcription factor action and cell reprogramming through chromatin
remodelling.
Introduction
The last decade was rich in surprising discoveries about the organization and
function of the pituitary. Indeed, we realized that pituitary cells are organized in a
series of intimately associated homotypic cell networks that serve to coordinate
tissue response (Mollard et al. 2012). Further, the pituitary, like many other tissues,
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was found to contain a population of stem or progenitor cells that are maintained in
adult tissues (Rizzoti 2015); this population of pituitary progenitors itself forms a
homotypic network that is primarily organized around the cleft between the inter-
mediate and anterior pituitary (Gremeaux et al. 2012). Signals that activate the
progenitors to either proliferate or differentiate are still being investigated, but
clearly these mechanisms provide a unique opportunity to think about new thera-
peutic perspectives to treat pituitary hormone deficiencies.
To capitalize on the properties of pituitary stem or progenitor cells for any kind
of replacement therapy requires that we understand the unique properties of these
cells and, most importantly, the mechanisms that engage stem cells into differen-
tiation pathways. Pituitary progenitors can differentiate into each of the pituitary
lineages (Fauquier et al. 2008); the challenge is then to understand the precise
requirements for differentiation into each lineage. While a number of critical
transcription factors have been identified for their role in terminal differentiation
of most lineages (Rizzoti 2015), such as Pit1, Tpit and SF1, the initial events of
entry into differentiation are the ones that we least understand presently.
This review will focus on one particular factor that appears to represent such an
initial event for engagement into the differentiation pathway, Pax7, which selects
intermediate lobe identity. Pax7 is unique among the transcription factors presently
identified for a role in pituitary cell differentiation in that it possesses pioneer
activity (Budry et al. 2012). Few transcription factors have the pioneer ability to
bind “closed” or compacted chromatin and to trigger chromatin remodeling of
regulatory sequences, thus opening not only chromatin structure but, most impor-
tantly, a new program of gene expression (Iwafuchi-Doi and Zaret 2014).
Escaping Stemness
Stem cells, whether pluripotent or tissue-specific, have unique properties with
regards to basic cell physiology compared to differentiated cells (De Los Angeles
et al. 2015). The engagement of stem cells into a differentiation pathway thus
implies an important switch for many cellular functions in addition to the gain of
expression for the unique genetic program of the chosen differentiation path. For
example, this can include a switch in energy metabolism (Kohli and Passegue
2014); for pituitary progenitors, it was shown that the control of cell cycle
re-entry is very different in progenitors compared to differentiated cells (Bilodeau
et al. 2009). Indeed during normal mouse development, pituitary progenitors
marked by expression of Sox2 (Fauquier et al. 2008) exit the cell cycle under the
action of the Cip-Kip inhibitor p57Kip2 whereas, upon differentiation, the role of
keeper of cell cycle re-entry is taken over by the related p27Kip1 (Fig. 1a). Although
replacing one inhibitor by a related one may appear as switching between redundant
regulators, the situation is likely more complex, since knockout mice for p57Kip2 do
eventually switch-on expression of p27Kip1 with rescue of some differentiated cells;
however, in the delayed progenitor compartment where this switch has not
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Fig. 1 Role of Pax7 in pituitary development. (a) The role of Pax7 in normal pituitary develop-
ment is depicted in the context of the engagement of Sox2-positive pituitary progenitors into
differentiation pathways. Pituitary progenitors are present throughout the pituitary primordium,
Rathke’s pouch, and the early pituitary depicted here at day e11.5 of mouse embryonic develop-
ment. The Sox2-positive progenitors (green) proliferate and, starting at e12, a group of Sox2-
negative, p57Kip2- and cyclinE-positive cells (white) appears on the ventral side of the pituitary
cleft: these cells have features of transitory precursors. The first differentiated cells appear on the
ventral surface of the developing anterior lobe: these are Tpit-positive corticotropes (blue) that no
longer express p57Kip2 and CyclinE but rather p27Kip1. Starting at e14, intermediate lobe (IL) cells
express Pax7 followed by Tpit and later POMC. Anterior lobe (AL) corticotropes never express
Pax7 and differentiate following expression of Tpit. (PL is posterior lobe). (b) Gain-of-function for
Pax7 performed in corticotrope AtT-20 cells reveals the pioneer transcription factor activity of
Pax7. The expression of Pax7 in AtT-20 cells reprograms the cells to become melanotrope-like
(Budry et al. 2012). The action of Pax7 on the AtT-20 epigenome results in activation of 2508 new
enhancers that have all the expected chromatin hallmarks; 824 of them can then recruit Tpit
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occurred, massive apoptosis occurs, which is suggestive of a critical role for p57Kip2
in leaving the stem status.
Little is known about this switch from stem to differentiated state but, during
development, it appears as sequential steps that are separated by a transitory period/
state where cells have lost markers of stemness such as Sox2 but not yet gained
markers of differentiation such as expression of terminal differentiation factors like
Pit1 and Tpit (Bilodeau et al. 2009). Cells undergoing this transitory period have
been highlighted in the developing anterior pituitary but effectors of this transition
remain to be identified. The big question is thus: what is happening to the genetic
program of these transitory precursors? Are they being pre-programmed for leaving
the stem state and for entry into one or the other pituitary differentiation pathway?
Is their epigenome being set for establishment of a differentiation program?
In the intermediate pituitary, a transcription factor essential for intermediate lobe
identity and melanotrope differentiation was identified and it appears to act within
this gap between stem and differentiation states. Indeed, the transcription factor
Pax7 is expressed immediately after extinction of Sox2, such that a small number of
co-expressing cells can be visualized in the developing mouse pituitary (Budry
et al. 2012). It is only about a half-day later that the driver of terminal differenti-
ation, Tpit, is expressed in Pax7-positive cells, leading to expression of
melanotrope genes (Fig. 1a).
Pax7 thus has the hallmark of a factor that would engage progenitors into a
differentiation pathway and prepare transitory precursors for implementation of the
terminal differentiation program that is itself directed by the Tbox factor Tpit. A
factor with similar properties has yet to be discovered in the anterior pituitary.
Intermediate Pituitary Identity
The intermediate lobe melanotropes are one of the two pituitary lineages that
express the single copy POMC gene. Terminal differentiation of both POMC
lineages, the melanotropes and the corticotropes of the anterior lobe, requires the
action of the Tbox transcription factor Tpit (Lamolet et al. 2001; Pulichino
et al. 2003). Consistent with this role of Tpit as driver of terminal differentiation,
Tpit is required for transcription of the POMC gene in both lineages and it acts
genome-wide on an extensive program of gene expression (Langlais et al. 2011).
Obviously by playing this role for both POMC lineages, Tpit cannot explain the
unique features of melanotrope compared to corticotropes, the two lineages fulfill-
ing entirely different biological functions and, accordingly, being regulated by very
different signals.
The quest for transcription factor(s) that may account for the unique program of
each lineage led to identification of Pax7 for its unique expression in the interme-
diate lobe melanotropes (Budry et al. 2012). The differentiation of most cell
lineages requires the combinatorial action of many transcription factors that
together control cell-specific gene expression. While it is in this context that Pax7
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was initially investigated, it rapidly became clear that Pax7 has far more reaching
actions on the epigenome and that it reprograms intermediate lobe cells for their
unique purpose. Hence in Pax7 knockout pituitaries, intermediate lobe cells still
differentiate under the action of Tpit but, being deprived of Pax7, the cells switch
fate and differentiate into corticotropes (Budry et al. 2012). This process is exem-
plified by the failure to activate melanotrope-specific genes such as the PC2 gene,
which encodes the protein convertase responsible for cleaving ACTH into αMSH,
and also by repression of corticotrope-specific genes such as those for CRH and
vasopressin receptors. This situation is very different in comparison to the Tpit
knockout intermediate lobe, where cells fail to differentiate into either melanotrope
or corticotrope but stay, for the most part, in a limbo between stem and differentiated
states; for example, these cells co-express the two cell cycle inhibitors p57Kip2 and
p27Kip1, a situation that is never observed normally. Thus, Pax7 itself does not drive
expression of the differentiation program but rather sets the stage for Tpit action.
Pax7 Opens a New Enhancer Repertoire
The unique property of Pax7 to act as a pioneer transcription factor allows it to
pre-program intermediate lobe precursors towards the melanotrope identity that
will be later implemented by Tpit (Budry et al. 2012). The picture that is emerging
with regards to pioneer factor action is still fragmentary, but the few pioneers that
have been characterized may operate at different levels to remodel chromatin.
Whereas the pluripotency factors Sox2, Oct4 and Klf4 initiate chromatin
remodeling over large spans of the genome (Soufi et al. 2012), factors like FoxA
(Cirillo et al. 2002), C/EBPα (van Oevelen et al. 2015), Ascl1(Wapinski et al. 2013)
and Pax7 that are involved in specific-tissue programming act primarily on the
enhancer repertoire by both locally opening chromatin at some enhancers and
closing others for activity. The opening or priming of a new enhancer repertoire
will de facto implement the possibility for a new program of gene expression and,
indeed, this is what is observed in pituitary cells following Pax7 action: Tpit now
gains access to a completely new set of enhancers (Fig. 1b). In gain-of-function
experiments performed in AtT-20 cells, Pax7 triggered the local appearance of
active chromatin marks at ~2500 enhancers and, of those, 824 became new targets
of Tpit. Genome-wide, Pax7 targeted an enhancer repertoire that largely (73%)
overlapped the Tpit target repertoire (Budry et al. 2012). The PC2 (PCSK2) locus
provides a good example of this: indeed in normal corticotrope AtT-20 cells, this
gene is inactive and its enhancer bears no mark of active chromatin. Following Pax7
action, an enhancer located 146Kb upstream of the PC2 transcription start site
became active, as revealed by a variety of chromatin marks. Indeed, the enhancer
acquired a bimodal distribution of histone H3K4me1 and the enhancer DNA
became accessible where it was depleted of nucleosome. Also, the general
co-activator p300 was recruited to the enhancer together with Tpit (Fig. 1b). This
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evolutionarily conserved enhancer thus has all the hallmarks of a Pax7- and Tpit-
dependent enhancer (Budry et al. 2012).
In contrast to the pluripotency factors that have large-scale effects on chromatin
organization, the action of Pax7 is restricted to a subset of enhancer domains. It is
interesting that, in the AtT-20 cell gain-of-function experiments, Pax7 also partially
repressed expression of corticotrope-specific genes and this was accompanied by a
quantitative decrease in chromatin marks. However, the extinction of corticotrope-
specific enhancers was at best partial in this model. Nonetheless, these observations
indicate that Pax7 has the ability to not only activate a subset of enhancers but also
to repress others, a property that is shared with other pioneer factors (Watts
et al. 2011; Wang et al. 2015).
The Essence of Pioneering
The critical property of pioneer factors is that they can access their target DNA
sequence in so-called “closed” or compacted heterochromatin. This unique prop-
erty was well illustrated for Pax7 in comparison to Tpit at the PC2 gene -146Kb
enhancer, where Tpit could not gain access to its well-conserved palindromic target
sequence if Pax7 had not previously directed local chromatin remodeling of the
enhancer (Budry et al. 2012). How pioneer factors gain access to their sites in
“closed” chromatin remains largely open to question. While some target binding
sites may find themselves exposed on the surface of nucleosomal DNA, the random
possibility of such positioning argues against this sole mechanism in view of the
high selectivity exerted by pioneer factors. Some pioneers such as FoxA may
initially bind its targets with decreased specificity to scan the genome and then
bind more firmly at pioneering sites (Soufi et al. 2015), but this still does not explain
why a specific subset of sites is selected. The winged helix DNA binding domain of
FoxA factors may mimic the structure of the histone H1 linker that interacts with
DNA to stabilize interaction with nucleosomal DNA (Cirillo and Zaret 2007), but
this model will not apply to all pioneers such as for Pax7. Some factors interact with
core histones, which may stabilize their association with chromatin (Cirillo
et al. 2002; Fiedler et al. 2008). Other factors like the Sox family interact with
the minor groove of DNA and that may facilitate recognition of target sequences on
nucleosomes, but again, this property is not relevant for all pioneers.
For the melanotrope-specific enhancers pioneered by Pax7, the analysis of
enhancers that contain only one sequence motif for Pax7 binding showed that the
group of enhancers that have a so-called composite motif was specifically associ-
ated with pioneering sites (Budry et al. 2012). This composite target site contained
each of the DNA sequences corresponding to the two DNA binding domains of
Pax7, the paired and the homeo domains. In contrast, the enhancers that contained
only the paired or homeodomain target sequence were primarily associated with
enhancers that were already accessible and targeted by Pax7 for transcriptional
activation without pioneering (Budry et al. 2012). Since the composite site was
118 J. Drouin
longer than either paired or homeodomain target sites, it is possible that higher
affinity for this site may contribute to the ability to pioneer chromatin remodeling.
Alternatively, it may also be that Pax7 interaction with the composite site involves a
unique conformation of the Pax7 DNA binding domains that is itself required to
initiate pioneering events.
Indeed, a unique conformation of the pioneer may be needed to recruit chroma-
tin remodeling complexes that initiate the replacement of modified histone from
repressive to active forms of histones. The sequence of biochemical changes
required to establish a new stable chromatin environment at active enhancers
remains poorly defined. In some systems, changing the chromatin environment
requires passage through DNA replication, hence stripping of chromatin to
re-establish a new chromatin environment (MacAlpine and Almouzni 2013;
Nashun et al. 2015). It is an open question whether passage through DNA replica-
tion is needed for all pioneers (Iwafuchi-Doi and Zaret 2014), but for Pax7, the
activation of target genes that require pioneering is far slower than for transcrip-
tional activation of enhancers/genes that are already in an open active chromatin
conformation. Hence, the action of Pax7 on chromatin remodeling may require
passage through DNA replication.
Succeeding at Multiple Choices or Avoiding Cellular
Schizophrenia
Pax7 is an interesting study case for pioneering. Indeed, we have shown a critical
role for Pax7 in the establishment of intermediate pituitary identity and setting-up
of the melanotrope program of gene expression, but the same Pax7 is also critical
for the myogenic program of gene expression, where it is expressed at the transition
between progenitor and differentiated skeletal muscles (Buckingham and Rigby
2014). These two entirely different functions of Pax7 are not compatible with each
other and, despite the ability of Pax7 to recognize its target DNA sites in hetero-
chromatin, it would need to distinguish the pituitary versus muscle targets in order
to appropriately play its role in each tissue. How is this achieved? There is currently
no clue on how this discrimination is exerted! The myogenic targets of Pax7 are not
bound by Pax7 in pituitary cells, despite the fact that a large group of Pax7 target
sites present in heterochromatin (marked with high levels of histone H3K9me3, the
hallmark of heterochromatin) are bound by Pax7 in pituitary cells. Unexplainably,
the myogenic targets of Pax7 exhibit lower levels of the repressive H3K9me3 in the
same pituitary cells and yet are not bound by Pax7. Without providing an explana-
tion, these observations nonetheless clearly indicate that we have much to learn
about the nature of so-called “closed” chromatin and that there likely are many
flavors of heterochromatin that remain to be defined.
Epigenetic Mechanisms of Pituitary Cell Fate Specification 119
Future Challenges
The above discussion has illustrated how pioneer transcription factors are important
to implement the developmental program through their unique properties to (1) rec-
ognize their DNA targets on “closed” chromatin and (2) initiate chromatin
remodeling either in a localized fashion at specific enhancers or more broadly on
large genomic domains. It is critical to understand these processes in order to master
cellular reprogramming for therapeutic uses.
In the context of pituitary development, we have reason to believe that there may
be one or more pioneer factors that establish competence towards anterior pituitary
lineages, and we would expect these factors to exert their critical function during
the developmental window when fetal pituitary progenitors have lost expression of
stem cell markers such as Sox2 but not yet gained expression of terminal differen-
tiation drivers such Tpit or Pit1. Is there one pioneer for anterior pituitary identity
that allows differentiation toward each of the five anterior lobe lineages or are there
two for each of the related subgroups of lineages, the gonadotrope and corticotrope
subgroup and the Pit-dependent subgroup? These are important questions that
demand investigation.
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